Andrew Huberman: Peptides, Sleep Tech, and the End of Obesity

The conversation explores the increasing consumer interest in personalized health, the role of media and technology, and future directions in proactive healthcare. Dr. Andrew Huberman and Daisy Wolf discuss the shift from "sex or vanity drugs" to a broader interest in health, driven by breakthrough supplements, the fitness industry's collision with mainstream medicine, and the impact of COVID-19. Huberman highlights the importance of circadian biology, tools for managing anxiety, and the influence of media on health perceptions. They delve into the peptide space, including GLP-1 drugs and others like BPC-157 and Melanotan, weighing their potential benefits and risks. Looking ahead, they envision a future where technology allows real-time monitoring and manipulation of biomarkers like cortisol, along with personalized interventions for sleep and focus.